Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773713 | 0.85 | GABRA5 (0.50) | GABRA5GPBAR1ALDH1A1 | |
| SCHEMBL286403 | 0.83 | GABRA5 (0.52) | GABRA5PTGS2PTGS1GPBAR1KMT2A | |
| SCHEMBL21834100 | 0.83 | GABRA5 (0.49) | GABRA5PTGS2PTGS1KMT2AATM | |
| SCHEMBL1776269 | 0.83 | PTGS2 (0.50) | GABRA5PTGS2PTGS1KMT2AATM | |
| SCHEMBL195699 | 0.83 | PTGS1 (0.58) | GABRA5PTGS2PTGS1KMT2AALDH1A1 | |
| SCHEMBL5775028 | 0.83 | GABRA5 (0.52) | GABRA5GPBAR1KMT2AALDH1A1 | |
| SCHEMBL3821682 | 0.80 | GABRA5 (0.52) | GABRA5GPBAR1ALDH1A1 | |
| SCHEMBL4790252 | 0.80 | GABRA5 (0.49) | GABRA5PTGS2ALDH1A1GABRG2GABRB3 | |
| SCHEMBL285552 | 0.78 | GABRA5 (0.55) | GABRA5 | |
| SCHEMBL21590459 | 0.78 | GABRA1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-112424196-A | Novel isoxazolyl ether derivatives as GABAA alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2019238633-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
| US-8163728-B2 | Pyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102414205-A | Isoxazole-pyrazole derivatives | HOFFMANN LA ROCHE | 2012-04-11 | — | — | CN | disclosed |
| EP-2427455-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127975-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286115-A1 | PYRAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | GABRA5 1/4885PTGS2 2551/4885PTGS1 2816/4885 |
| US-20100286115-A1 | PYRAZOLES | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885PTGS2 1849/4885PTGS1 1171/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | GABRA5 1/4885PTGS2 2555/4885PTGS1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.